Chemical formula: C₄₂H₆₅N₁₁O₁₂S₂ Molecular mass: 979.426 g/mol
Urofollitropin contains a highly purified preparation of urinary FSH extracted from the urine of postmenopausal women. FSH stimulates ovarian follicular growth and development as well as gonadal steroid production in women who do not have primary ovarian failure.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| G03GA04 | Urofollitropin | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| BRAVELLE Powder and solvent for solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Urofollitropin is an active ingredient of these brands:
Australia (AU)
Austria (AT)
Brazil (BR)Canada (CA)
Croatia (HR)
Cyprus (CY)
Ecuador (EC)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Lithuania (LT)Malta (MT)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Romania (RO)
Singapore (SG)South Africa (ZA)
Spain (ES)Tunisia (TN)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.